Mainz BioMed NV News - MYNZ

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today increasing demand from existing and prospective laboratory partners for its enhanced ColoAlert product that has been launched in July 2024 and is currently being commercialized across Europe and in select international markets. This advanced version of the Company’s colorectal cancer (CRC) screening test is set to become the standard offering for all existing partners, reflecting its proven benefits in optimizing screening efficiency and improving user experience.
Widespread Transition to Enhanced ColoAlert

One of the earliest partners to make the transition is GANZIMMUN Diagnostics, one of Germany’s premier laboratories, which licensed the ColoAlert test. GANZIMMUN will fully implement the enhanced version of the innovative DNA biomarker-based screening product by the beginning of next year, taking advantage of the significant improvements in sample processing and usability that have set a new industry benchmark.

Improving Customer Interest

Partners are particularly drawn to the enhanced features, such as the proprietary DNA stabilizing buffer that ensures reliable results despite varying sample volumes, and the streamlined collection devices that simplify at-home testing for users. These innovations have drastically reduced the need for retesting, offering faster turnaround times for patients, with results available in just 2–3 days from sample arrival.

Promotion at Key Medical Event

GANZIMMUN Diagnostics will showcase the enhanced ColoAlert at the 57th Medizinische Woche Baden-Baden, a medical congress in Germany focusing on complementary medicine, which takes place from October 30 to November 3, 2024. This underscores the increasing role of complementary medicine in cancer prevention and early detection. The event will provide an ideal platform to promote Mainz Biomed’s innovative DNA-based CRC screening test to medical professionals, integrative medicine practitioners, and researchers interested in advanced diagnostic solutions.
"We are excited to support GANZIMMUN in introducing the enhanced ColoAlert at such a prestigious event," stated Tarrin Khairi-Taraki, VP Commercial Operations at Mainz Biomed. "The 57th Medizinische Woche Baden-Baden provides an excellent opportunity to demonstrate the importance of early colorectal cancer detection and how our innovations are making this process more efficient."

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Mainz BioMed NV (MYNZ)

Professional-Grade Tools, for Individual Investors.

MYNZ News

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference

Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update

Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel

MYNZ Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists